Bergenbio ASA (id:10486 BGBIO)
8.42 NOK
Opening hours: 09:00 - 16:20 (Central European Standard Time: 12/24/2024 5:56:58 PM)
Exchange closed, opens in 15 hours 2 minutes
About Bergenbio ASA
Market Capitalization 490.15M
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
| Headquarters (address) |
MOellendalsbakken 9 Bergen 5009 Norway |
| Phone | 47 55 96 11 59 |
| Website | https://www.bergenbio.com |
| Employees | 15 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | BGBIO |
| Exchange | Oslo Stock Exchange |
| Currency | NOK |
| 52 week range | 5.62 - 35.80 |
| Market Capitalization | 490.15M |
| P/E trailing | 3.00 |
| P/E forward | -2.15 |
| Price/Sale | 940.79 |
| Price/Book | 2.65 |
| Beta | 1.64 |
| EPS | -1.74 |
| EPS Norway (ID:238, base:161) | 8.25 |